PRONOUNCE Randomized OpenLabel Phase III Study of FirstLine

PRONOUNCE: Randomized, Open-Label, Phase III Study of First-Line Pemetrexed + Carboplatin Followed by Maintenance Pemetrexed versus Paclitaxel + Carboplatin + Bevacizumab Followed by Maintenance Bevacizumab in Patients ith Advanced Nonsquamous Non–Small-Cell Lung Cancer Ralph G. Zinner, MD, Coleman K. Obasaju, MD, Ph. D, David R. Spigel, MD, Robert W. Weaver, MD, J. Thaddeus Beck, MD, David M. Waterhouse, MD, MPH, Manuel R. Modiano, MD, Borys Hrinczenko, MD, Ph. D, Petros G. Nikolinakos, MD, Jingyi Liu, Ph. D, Andrew G. Koustenis, BPharm, Katherine B. Winfree, Ph. D, Symantha A. Melemed, Ph. D, Susan C. Guba, MD, Waldo I. Ortuzar, MD, Durisala Desaiah, Ph. D, Joseph A. Treat, MD, Ramaswamy Govindan, MD, Helen J. Ross, MD Journal of Thoracic Oncology Volume 10 Issue 1 Pages 134 -142 (January 2015) DOI: 10. 1097/JTO. 0000000366 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions